ArticleJournal of managed care & specialty pharmacy2022

The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.

Holly Cranmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.